One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma

Eur J Ophthalmol. 2012 Mar-Apr;22(2):226-35. doi: 10.5301/EJO.2011.7733.

Abstract

Purpose: LINAC-based stereotactic radiosurgery (SRS) of posterior uveal melanoma is a conservative method to treat uveal melanoma.

Methods: This was a retrospective clinic-based study of patients with posterior uveal melanoma in stage T2/T3 who underwent 1-day session SRS at LINAC accelerator or SRS plus combined methods from 2001 to 2008.

Results: Thirty-nine patients with posterior uveal melanoma were treated with SRS (age 25-80 years, median 54 years). Median tumor volume at baseline was 0.6 cm3 (range 0.2-1.3 cm3). The therapeutic dose (TD) was 35.0 Gy, median of maximal dose applied was 49.0 Gy (range 37.0-60.0 Gy). Patient data were analyzed in groups: group 1, single SRS irradiation; group 2, SRS with subsequent endoresection or cyclectomy or additional transpupillary thermotherapy (TTT) or brachytherapy by Ru106 plaques; group 3a, enucleation after single SRS; group 3b, enucleation after SRS and endoresection/cyclectomy or TTT or brachytherapy Ru106. In patients with visual acuity of 20/40 or better, the median rate of best-corrected visual acuity (BCVA) decline was higher than that of the total and significantly higher than the rate of decline in the complementary group of patients with BCVA less than 20/40 (p=0.0077; Mann-Whitney U test).

Conclusions: One-step LINAC-based SRS with a single dose 35.0 Gy is a method to treat middle-stage posterior uveal melanoma and to preserve the eye globe or as the first step of combined methods: irradiation before endoresection or cyclectomy.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brachytherapy
  • Eye Enucleation
  • Female
  • Humans
  • Hyperthermia, Induced
  • Male
  • Melanoma / pathology
  • Melanoma / surgery*
  • Middle Aged
  • Neoplasm Staging
  • Particle Accelerators
  • Radiosurgery*
  • Radiotherapy Dosage
  • Retrospective Studies
  • Ruthenium Radioisotopes / therapeutic use
  • Treatment Outcome
  • Uveal Neoplasms / pathology
  • Uveal Neoplasms / surgery*
  • Visual Acuity / physiology

Substances

  • Ruthenium Radioisotopes